AIMS: @entity8142 agonists (GLP-1RAs) are associated with gastrointestinal adverse events (AEs), although type and frequency may differ across the class. We characterized @entity344 with different GLP-1RAs. METHODS: Two retrospective intent-to-treat analyses of 6-month @entity1 -level data were conducted. Data from three studies comparing exenatide once weekly (QW; n   =   617) with exenatide twice daily (BID; n   =   606) were pooled, and one (DURATION-6) comparing exenatide QW (n   =   461) with @entity32267 (n   =   450) was analyzed separately. @entity1 -reported @entity344 were classified as upper or lower, AE incidences and timing were determined, subgroups were analyzed, and associations of @entity344 with efficacy were examined. RESULTS: Nausea was the most common gastrointestinal AE for all treatments. Fewer exenatide QW-treated versus exenatide BID- or @entity32267 -treated @entity1 reported @entity344 (34% vs. 45% and 25% vs. 41%, respectively; both p   <   0.0001). Fewer exenatide QW-treated @entity1 reported upper plus lower events than @entity32267 -treated @entity1 (p   <   0.001); the difference between exenatide QW and BID was not significant. Within each group, more females than males reported @entity344 . Events occurrred early and were predominantly mild. HbA1c reductions were similar for @entity1 with or without @entity344 . Weight loss was greater for @entity1 with @entity344 with exenatide QW and exenatide BID (p   <   0.05); no difference was observed in DURATION-6. CONCLUSIONS: @entity344 were less frequent with exenatide QW versus exenatide BID or @entity32267 , and combined upper and lower events occurred less often. @entity344 were typically mild and occurred early. @entity344 did not affect glycemic control but may be associated with greater weight loss.

Upper and/or lower gastrointestinal adverse events with XXXX agonists: incidences and consequences.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient'] @entity8142 :: ('2740', 'Gene') :: ['Glucagon-like peptide-1 receptor'] @entity32267 :: ('MESH:C439759', 'Chemical') :: ['liraglutide'] @entity344 :: ('MESH:D005767', 'Disease') :: ['Gastrointestinal AEs', 'gastrointestinal AEs']
@entity8142 :: (2740,Gene) :: ['GLP-1 receptor']
